MCID: ISL001
MIFTS: 50

Islet Cell Tumor

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Islet Cell Tumor

MalaCards integrated aliases for Islet Cell Tumor:

Name: Islet Cell Tumor 38 12 55 15 73
Well Differentiated Pancreatic Endocrine Tumor 73
Malignant Neoplasm of Endocrine Pancreas 73
Malignant Tumor of Endocrine Pancreas 12
Malignant Pancreatic Endocrine Tumor 12
Pancreatic Endocrine Carcinoma 73
Pancreatic Endocrine Neoplasm 12
Endocrine Pancreas Cancer 12
Carcinoma Islet Cell 55
Islet Cell Neoplasm 12
Adenoma, Islet Cell 44
Islet Cell Tumour 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1799
ICD10 33 C25.4 D13.7
MeSH 44 D007516
NCIt 50 C27031
SNOMED-CT 68 76345009

Summaries for Islet Cell Tumor

Disease Ontology : 12 A pancreatic cancer that is located in the pancreatic islet cells.

MalaCards based summary : Islet Cell Tumor, also known as well differentiated pancreatic endocrine tumor, is related to pancreatic endocrine carcinoma and vipoma. An important gene associated with Islet Cell Tumor is SST (Somatostatin), and among its related pathways/superpathways are Signaling by GPCR and Presynaptic function of Kainate receptors. The drugs Sunitinib and Everolimus have been mentioned in the context of this disorder. Affiliated tissues include pancreas, pancreatic islet and liver, and related phenotypes are homeostasis/metabolism and endocrine/exocrine gland

Related Diseases for Islet Cell Tumor

Diseases related to Islet Cell Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 179)
# Related Disease Score Top Affiliating Genes
1 pancreatic endocrine carcinoma 32.0 INS SST
2 vipoma 32.0 CHGA GAST SST VIP
3 somatostatinoma 31.9 CALCA CHGA INS SST VIP
4 insulinoma 31.7 CHGA IAPP INS MEN1 SST
5 neuroendocrine tumor 31.2 CALCA CHGA GAST MEN1 SST
6 zollinger-ellison syndrome 30.2 CHGA GAST MEN1 SST
7 glucagonoma 30.2 CHGA SST VIP
8 adenoma of the pancreas 30.1 CHGA SST
9 multiple endocrine neoplasia 30.0 CALCA CHGA MEN1
10 lung oat cell carcinoma 29.9 CALCA CHGA
11 gastrointestinal stromal tumor 29.9 CHGA IGF2 MEN1
12 insulin-like growth factor i 29.8 IGF2 INS SST
13 acromegaly 29.8 IGF2 INS MEN1 SST
14 hyperglycemia 29.7 IAPP INS SST
15 pancreatic somatostatinoma 29.6 CALCA MEN1 SST
16 peptic ulcer disease 29.6 GAST MEN1
17 pheochromocytoma 29.5 CALCA CHGA MEN1 SST VIP
18 multiple endocrine neoplasia, type i 29.5 CHGA GAST INS MEN1 SST VIP
19 diabetes mellitus, noninsulin-dependent 29.4 IAPP IGF2 INS SST
20 carcinoid syndrome 29.4 CALCA CHGA MEN1 SST
21 diabetes mellitus 29.2 IAPP INS MEN1 SST
22 hyperparathyroidism 29.0 CALCA CHGA GAST MEN1 PTHLH
23 gastrinoma 29.0 CHGA GAST INS MEN1 SST VIP
24 pheochromocytoma--islet cell tumor syndrome 12.5
25 pancreatic neuroendocrine tumor 11.9
26 mahvash disease 11.4
27 hypoglycemia 10.7
28 hyperinsulinism 10.4
29 diarrhea 10.3
30 pylorospasm 10.2 GAST SST
31 postcholecystectomy syndrome 10.2 GAST SST
32 autoimmune atrophic gastritis 10.2 CHGA GAST
33 gastrointestinal neuroendocrine tumor 10.2 CHGA SST
34 pituitary carcinoma 10.2 CHGA SST
35 duodenogastric reflux 10.2 GAST SST
36 retinitis pigmentosa 40 10.2 GAST SST
37 goblet cell carcinoid 10.2 CHGA GAST
38 pernicious anemia 10.2 GAST SST
39 pancreatoblastoma 10.2 CHGA SST
40 postural hypotension 10.2 INS SST
41 non-functioning pancreatic endocrine tumor 10.2 CHGA GAST
42 duodenitis 10.2 GAST INS
43 hyperpituitarism 10.2 INS SST
44 dumping syndrome 10.2 INS SST
45 type 1 diabetes mellitus 2 10.2 IGF2 INS
46 hypoglycemic coma 10.2 IGF2 INS
47 spinal meningioma 10.2 CHGA IGF2
48 spinal canal and spinal cord meningioma 10.2 CHGA IGF2
49 functional gastric disease 10.2 INS SST
50 ileum cancer 10.2 GAST SST

Graphical network of the top 20 diseases related to Islet Cell Tumor:



Diseases related to Islet Cell Tumor

Symptoms & Phenotypes for Islet Cell Tumor

MGI Mouse Phenotypes related to Islet Cell Tumor:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.91 CHGA GAST IAPP IGF2 INS MEN1
2 endocrine/exocrine gland MP:0005379 9.87 CHGA GAST IGF2 INS MEN1 PTHLH
3 digestive/alimentary MP:0005381 9.85 GAST IGF2 INS MEN1 PTHLH SST
4 immune system MP:0005387 9.76 GAST IAPP IGF2 INS MEN1 PTHLH
5 mortality/aging MP:0010768 9.56 CHGA GAST IGF2 INS MEN1 PTHLH
6 reproductive system MP:0005389 9.1 CHGA IGF2 INS MEN1 PTHLH VIP

Drugs & Therapeutics for Islet Cell Tumor

Drugs for Islet Cell Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 166)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 557795-19-4, 341031-54-7 5329102
2
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
3
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
4
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
5
Levoleucovorin Approved, Investigational Phase 4,Phase 2,Phase 3 68538-85-2
6
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3 61825-94-3 43805 6857599 5310940 9887054
7
leucovorin Approved Phase 4,Phase 2,Phase 3 58-05-9 6006 143
8
Fluorouracil Approved Phase 4,Phase 2,Phase 3 51-21-8 3385
9
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 51110-01-1, 38916-34-6 53481605
10
Pancrelipase Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 53608-75-6
11
Streptozocin Approved, Investigational Phase 4,Phase 3,Phase 2 18883-66-4 29327
12
Capecitabine Approved, Investigational Phase 4,Phase 2,Phase 1 154361-50-9 60953
13
Dacarbazine Approved, Investigational Phase 4,Phase 2,Phase 1 4342-03-4 5351166
14
Temozolomide Approved, Investigational Phase 4,Phase 2,Phase 1 85622-93-1 5394
15
Pasireotide Approved Phase 4,Phase 2,Phase 1 396091-73-9 9941444
16
Gemcitabine Approved Phase 4 95058-81-4 60750
17
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 59-30-3 6037
18 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
19 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
20 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1
21 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1
23 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1
26 Antiviral Agents Phase 4,Phase 2,Phase 1
27 Vitamin B9 Phase 4,Phase 2,Phase 3,Phase 1
28 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1
29 Folate Phase 4,Phase 2,Phase 3,Phase 1
30 Antimetabolites, Antineoplastic Phase 4,Phase 2,Phase 3,Phase 1
31 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
32 Hormones Phase 4,Phase 3,Phase 2,Phase 1
33 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
34 Hypoglycemic Agents Phase 4,Phase 2,Phase 1
35 pancreatin Phase 4,Phase 2,Phase 1,Not Applicable
36 Micronutrients Phase 4,Phase 2,Phase 1
37 Antidotes Phase 4,Phase 2
38 Vitamins Phase 4,Phase 2,Phase 1
39 Antineoplastic Agents, Alkylating Phase 4,Phase 2,Phase 1
40 Protective Agents Phase 4,Phase 2
41 Vitamin B Complex Phase 4,Phase 2,Phase 1
42 Alkylating Agents Phase 4,Phase 2,Phase 1
43 Trace Elements Phase 4,Phase 2,Phase 1
44 Insulin, Globin Zinc Phase 4,Not Applicable
45 insulin Phase 4,Not Applicable
46 Fluorodeoxyglucose F18 Phase 4,Phase 2
47 Hematinics Phase 4
48
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
49 lanreotide Approved Phase 3,Phase 2 108736-35-2
50
Dopamine Approved Phase 3 51-61-6, 62-31-7 681

Interventional clinical trials:

(show top 50) (show all 147)
# Name Status NCT ID Phase Drugs
1 Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors Unknown status NCT02759718 Phase 4
2 A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Completed NCT01525550 Phase 4 sunitinib
3 Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China Recruiting NCT02842749 Phase 4 everolimus
4 Nonfunctional Pancreatic NET and PET Imaging Recruiting NCT02621541 Phase 4
5 MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents Recruiting NCT03217097 Phase 4 Oxaliplatin-based chemotherapy;Alkylating-based chemotherapy
6 Pasireotide Treatment for Neuroendocrine Tumor Withdrawn NCT02779257 Phase 4 Pasireotide;Diazoxide
7 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
8 Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour Completed NCT00842348 Phase 3 lanreotide (Autogel formulation)
9 Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours Completed NCT00353496 Phase 3 lanreotide (Autogel formulation);Placebo
10 Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors Completed NCT00510068 Phase 3 Everolimus;Everolimus Placebo
11 A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET) Recruiting NCT02288377 Phase 2, Phase 3 lanreotide;Placebo
12 Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors Recruiting NCT02589821 Phase 3 Surufatinib
13 Efficacy and Safety of Everolimus and (STZ-5FU) Given One Upfront the Other Upon Progression in Advanced pNET Recruiting NCT02246127 Phase 3 Drug: Everolimus;STZ-5FU
14 18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety Recruiting NCT03042416 Phase 3 18F-DOPA
15 Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery Recruiting NCT03375320 Phase 3 Cabozantinib S-malate
16 Non-functioning Pancreatic Neuroendocrine Tumors in MEN1: Somatostatin Analogs Versus NO Treatment Not yet recruiting NCT02705651 Phase 3 Somatostatin-Analog
17 A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors Terminated NCT00428597 Phase 3 sunitinib malate;Placebo
18 Activity and Safety of Everolimus+Octreotide LAR+Metformin in Advanced Pancreatic Well-differentiated NETs Unknown status NCT02294006 Phase 2 Everolimus plus Octreotide LAR plus Metformin
19 Docetaxel With or Without Low-dose, Short Course Sunitinib in Refractory Solid Tumors Unknown status NCT01803503 Phase 2 Docetaxel;Sunitinib
20 Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer Unknown status NCT02188550 Phase 2 everolimus and letrozole
21 Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors Unknown status NCT02455596 Phase 2 Recombinant anti-tumor and anti-virus protein for injection (Novaferon)
22 A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With Everolimus Completed NCT02305810 Phase 2 Everolimus 10 mg daily
23 BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy. Completed NCT01658436 Phase 2 BEZ235 (Stage 1)
24 Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor Completed NCT01845675 Phase 2 temozolomide or dacarbazine-based chemotherapy, endostatin
25 68-Ga-labeled Octreotide Analogues PET in Duodenal-pancreatic Neuroendocrine Tumours Completed NCT01673906 Phase 2 Diagnostic work up
26 AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors Completed NCT01024387 Phase 2 AMG 479
27 Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Completed NCT01121562 Phase 2 Sunitinib
28 A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET) Completed NCT02806648 Phase 2 Palbociclib
29 Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery Completed NCT02101918 Phase 2
30 Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas Completed NCT00001165 Phase 2 combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin
31 Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
32 Interferon and Octreotide to Treat Zollinger-Ellison Syndrome and Advanced Non-B Islet Cell Cancer Completed NCT00001228 Phase 2 Interferon
33 Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET Completed NCT02231762 Phase 2 Lanreotide Autogel 120 mg;Temozolomide (TMZ)
34 Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy Completed NCT00363051 Phase 2 Everolimus 10 mg;Octreotide Depot
35 Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2 capecitabine;cisplatin;streptozocin
36 Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization Completed NCT00434109 Phase 2 Sunitinib malate
37 PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00017199 Phase 2 bortezomib
38 68Ga-OPS202 Study for Diagnostic Imaging of GEP NET Completed NCT02162446 Phase 1, Phase 2 satoreotide trizoxetan
39 AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2 AMG 706;octreotide
40 Pazopanib as Single Agent in Advanced NETs Completed NCT01280201 Phase 2 Pazopanib
41 The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid Completed NCT00001191 Phase 2 Pantoprazole;Omeprazole
42 Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET) Completed NCT00610129 Phase 2 MK-0646
43 KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors Completed NCT02250885 Phase 2 Selinexor
44 A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers Completed NCT02132468 Phase 2 fosbretabulin tromethamine
45 Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00027638 Phase 2 thalidomide
46 Sunitinib in Never-Smokers With Lung Adenocarcinoma Completed NCT01829217 Phase 2 Sunitinib
47 Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases Completed NCT00019786 Phase 2 isolated perfusion;melphalan
48 68Ga-DOTATATE PET Scan in Neuroendocrine Cancer Completed NCT01396382 Phase 2
49 A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor Recruiting NCT03204019 Phase 2 Tegafur and Temozolomide;Tegafur and Temozolomide combined with Thalidomide
50 177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors Recruiting NCT02736448 Phase 2 Capecitabine;Lu-PRRT;SS-LAR

Search NIH Clinical Center for Islet Cell Tumor

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: adenoma, islet cell

Genetic Tests for Islet Cell Tumor

Anatomical Context for Islet Cell Tumor

MalaCards organs/tissues related to Islet Cell Tumor:

41
Pancreas, Pancreatic Islet, Liver, Thyroid, Pituitary, Lung, Spinal Cord

The Foundational Model of Anatomy Ontology organs/tissues related to Islet Cell Tumor:

19
The Pancreatic Islet Cells

Publications for Islet Cell Tumor

Articles related to Islet Cell Tumor:

(show top 50) (show all 278)
# Title Authors Year
1
Late Onset of Non-islet Cell Tumor Hypoglycemia Managed via Multidisciplinary Treatment in a Patient with a Solitary Fibrous Tumor. ( 29526941 )
2018
2
Non-Islet Cell Tumor Hypoglycemia: A Rare Cause of Hypoglycemia in Pulmonary Sarcomatoid Cancer. ( 29492361 )
2017
3
A Case of Non-Islet Cell Tumor Hypoglycemia (NICTH) Associated with Gastrointestinal Stromal Tumor (GIST). ( 28900071 )
2017
4
Levels of glucose-regulatory hormones in patients with non-islet cell tumor hypoglycemia: including a review of the literature. ( 28529277 )
2017
5
Non-islet cell tumor hypoglycemia caused by a big insulin-like growth factor II- producing hepatocellular carcinoma:an autopsy case report. ( 27916774 )
2016
6
Non-islet cell tumor hypoglycemia caused by intrathoracic solitary fibrous tumor: a case report. ( 27061182 )
2016
7
Fatal hepatitis B reactivation in a patient with islet cell tumor on octreotide and sirolimus. ( 26487953 )
2015
8
Non-Islet Cell Tumor Hypoglycemia Is Caused by Big IGF-II in a Patient with a Carcinosarcoma of the Uterus. ( 26666605 )
2015
9
The Transformation of a Nonfunctioning Islet Cell Tumor of the Pancreas into a Proinsulinoma under Conditions of Lung Metastasis. ( 25832942 )
2015
10
Multiple hepatocellular adenomas presenting in a male 8 years post-pancreaticoduodenectomy for islet cell tumor of the pancreas. ( 25810673 )
2015
11
Recurrent Non-islet Cell Tumor Hypoglycemia Secondary to Recurrent Renal Sarcoma. ( 30263029 )
2015
12
Nonfunctional islet cell tumor of the pancreas in a patient with tuberous sclerosis: a case report with literature review. ( 24678435 )
2014
13
Characterization of a pancreatic islet cell tumor in a polar bear (Ursus maritimus). ( 25273481 )
2014
14
A 94-year-old man with recurrent hypoglycemia caused by non-islet cell tumor hypoglycemia (NICTH). ( 25780362 )
2014
15
Bioactive insulin-like growth factors as a possible molecular target for non-islet cell tumor hypoglycemia. ( 25535894 )
2014
16
Gastric neuroendocrine carcinoma with non-islet cell tumor hypoglycemia associated with enhanced production of insulin-like growth factor II. ( 23545670 )
2013
17
Management of Non-Islet-Cell Tumor Hypoglycemia: A Clinical Review. ( 24423303 )
2013
18
Nesidioblastosis and Pancreatic Non-functioning Islet Cell Tumor in an Adult with Type 2 Diabetes Mellitus. ( 24255640 )
2013
19
Non-islet cell tumor-induced hypoglycemia: a report of five cases and brief review of the literature. ( 24616774 )
2013
20
Metastatic Insulinoma Following Resection of Nonsecreting Pancreatic Islet Cell Tumor: A Case Report and Review of the Literature. ( 26425568 )
2013
21
Surgical treatment of pancreatic islet cell tumor: report of 44 cases. ( 24719954 )
2013
22
Non-Islet Cell Tumor-Induced Hypoglycemia Associated with Macronodular Pulmonary Metastases from Poorly Differentiated Thyroid Carcinoma. ( 23697382 )
2013
23
Non-islet cell tumor hypoglycemia associated with recurrent carcinosarcoma of the ovary. ( 23512392 )
2013
24
Recurrent solitary fibrous tumor of the pleura with malignant transformation and non-islet cell tumor-induced hypoglycemia due to paraneoplastic overexpression and secretion of high-molecular-weight insulin-like growth Factor II. ( 23207122 )
2012
25
Gastrointestinal stromal tumor of the pelvic soft tissue presenting with symptomatic hypoglycemia: A case report and brief review of current literature of non-islet cell tumor-induced hypoglycemia. ( 24371628 )
2012
26
Severe hypoglycemia with "Big"-IGF-2 oversecretion by a giant phyllode tumor of the breast: a rare case of non-islet cell tumor-induced hypoglycemia (NICTH). ( 22867750 )
2012
27
Non-islet cell tumor hypoglycemia at the second recurrence of malignant solitary fibrous tumor in the retroperitoneum and pelvis: a case report. ( 22949904 )
2012
28
Diabetic ketoacidosis with concurrent pancreatitis, pancreatic I^ islet cell tumor, and adrenal disease in an obese ferret (Mustela putorius furo). ( 21838985 )
2011
29
Pancreatic and peri-pancreatic lesions mimic pancreatic islet cell tumor in multidetector computed tomography. ( 21740785 )
2011
30
Retrospective Review of Cross Sectional Imaging Findings of Pancreatic Non-functional Islet Cell Tumor (NFICT) and its Hepatic Metastases. ( 22043378 )
2011
31
Non-islet cell tumor hypoglycemia associated with uterine leiomyomata. ( 21550955 )
2011
32
Hepatic abscess after yttrium-90 radioembolization for islet-cell tumor hepatic metastasis. ( 19688373 )
2010
33
A case of gastric cancer with non-islet cell tumor hypoglycemia detected by insulin-like growth factor II. ( 20618739 )
2010
34
Metastatic pancreatic polypeptide-secreting islet cell tumor in a dog. ( 20698942 )
2010
35
Non-islet cell tumor hypoglycemia. ( 19345293 )
2009
36
Successful control of intractable hypoglycemia using rapamycin in an 86-year-old man with a pancreatic insulin-secreting islet cell tumor and metastases. ( 19567519 )
2009
37
Pancreatic islet cell tumor secreting insulin-like growth factor type-II in a dog. ( 19780935 )
2009
38
Homozygous P86S mutation of the human glucagon receptor is associated with hyperglucagonemia, alpha cell hyperplasia, and islet cell tumor. ( 19657311 )
2009
39
Hypoglycemia associated with the production of insulin-like growth factor II in a pancreatic islet cell tumor: a case report. ( 18490836 )
2008
40
Islet cell tumor of the pancreas: increasing diagnosis after instituting ultrasonography-guided fine needle aspiration. ( 18323274 )
2008
41
Spectrum of functioning islet cell tumor on multislice computed tomography: experience on 70 patients. ( 18437902 )
2008
42
Successful treatment of non-islet cell tumor hypoglycemia in hepatocellular carcinoma with doxorubicin. ( 18278497 )
2008
43
Spontaneous pancreatic islet cell tumor in a black and white colobus monkey (Colobus guereza kikuyuensis). ( 18269522 )
2008
44
Nesidioblastosis and hyperplasia of alpha cells, microglucagonoma, and nonfunctioning islet cell tumor of the pancreas: review of the literature. ( 18437091 )
2008
45
Non-islet-cell tumor hypoglycemia and lactic acidosis in a child with congenital HIV and Burkitt's lymphoma. ( 18825882 )
2008
46
Generation and characterization of islet cell tumor in pTet-on/pTRE-SV40Tag double-transgenic mice model. ( 17697978 )
2007
47
Solitary fibrous tumor associated with non-islet cell tumor hypoglycemia. ( 17588442 )
2007
48
Non-islet cell tumor hypoglycemia in a patient with poorly differentiated thyroid cancer. ( 17274758 )
2007
49
Severe hypoglycemia induced by IGF-II producing non-islet cell tumor. ( 17603253 )
2007
50
Differential diagnosis of non-functional islet cell tumor and pancreatic carcinoma with sonography. ( 17412543 )
2007

Variations for Islet Cell Tumor

Expression for Islet Cell Tumor

Search GEO for disease gene expression data for Islet Cell Tumor.

Pathways for Islet Cell Tumor

GO Terms for Islet Cell Tumor

Cellular components related to Islet Cell Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 CALCA CHGA GAST IAPP IGF2 INS
2 extracellular region GO:0005576 9.28 CALCA CHGA GAST IAPP IGF2 INS

Biological processes related to Islet Cell Tumor according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.85 IGF2 INS PTHLH VIP
2 G protein-coupled receptor signaling pathway GO:0007186 9.8 CALCA GAST IAPP INS PTHLH SST
3 positive regulation of protein kinase B signaling GO:0051897 9.71 IAPP IGF2 INS
4 positive regulation of MAPK cascade GO:0043410 9.65 IAPP IGF2 INS
5 adenylate cyclase-activating G protein-coupled receptor signaling pathway GO:0007189 9.62 CALCA IAPP PTHLH VIP
6 response to heat GO:0009408 9.57 CALCA SST
7 positive regulation of mitotic nuclear division GO:0045840 9.56 IGF2 INS
8 cell-cell signaling GO:0007267 9.55 CALCA IAPP INS PTHLH SST
9 positive regulation of blood vessel diameter GO:0097755 9.54 CALCA INS VIP
10 osteoblast development GO:0002076 9.52 MEN1 PTHLH
11 positive regulation of glycogen biosynthetic process GO:0045725 9.51 IGF2 INS
12 positive regulation of insulin receptor signaling pathway GO:0046628 9.49 IGF2 INS
13 negative regulation of bone resorption GO:0045779 9.46 CALCA IAPP
14 negative regulation of blood vessel diameter GO:0097756 9.43 CHGA INS
15 amylin receptor signaling pathway GO:0097647 9.4 CALCA IAPP
16 cellular protein metabolic process GO:0044267 9.35 CALCA IAPP IGF2 INS MEN1
17 regulation of signaling receptor activity GO:0010469 9.23 CALCA GAST IAPP IGF2 INS PTHLH

Molecular functions related to Islet Cell Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 insulin receptor binding GO:0005158 9.26 IGF2 INS
2 hormone activity GO:0005179 9.23 CALCA GAST IAPP IGF2 INS PTHLH
3 insulin-like growth factor receptor binding GO:0005159 9.16 IGF2 INS
4 peptide hormone receptor binding GO:0051428 8.96 PTHLH VIP

Sources for Islet Cell Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....